Table 4.
Multivariate analysis for progression-free survival and overall survival, including depth of response.
| Progression-free survival | Overall survival | |||
|---|---|---|---|---|
| Variable | Hazard ratio (95% CI) |
P-value | Hazard ratio (95% CI) |
P-value |
| Treatment | .11 | .14 | ||
| GC | 1 | 1 | ||
| GS | 0.80 (0.61-1.05) | 0.82 (0.62-1.07) | ||
| Sex | .43 | .99 | ||
| Male | 1 | 1 | ||
| Female | 0.89 (0.67-1.19) | 1.00 (0.76-1.31) | ||
| Age | .07 | .61 | ||
| <65 years | 1 | 1 | ||
| ≥65 years | 0.77 (0.58-1.02) | 0.93 (0.71-1.22) | ||
| ECOG PS | .92 | .06 | ||
| 0 | 1 | 1 | ||
| 1 | 1.02 (0.73-1.42) | 1.34 (0.99-1.80) | ||
| Primary tumor site | .32 | .27 | ||
| Gallbladder | 1 | 1 | ||
| Non-gallbladder | 0.86 (0.65-1.16) | 0.86 (0.65-1.13) | ||
| Biliary drainage | .50 | .18 | ||
| Absent | 1 | 1 | ||
| Present | 1.11 (0.83-1.49) | 1.22 (0.91-1.62) | ||
| Prior surgical resection | .40 | .19 | ||
| Absent | 1 | 1 | ||
| Present | 0.85 (0.58-1.25) | 0.77 (0.53-1.13) | ||
| Diameter of measurable target lesions | .42 | .75 | ||
| <51 mm | 1 | 1 | ||
| ≥51 mm | 0.88 (0.65-1.20) | 0.95 (0.71-1.28) | ||
| CEA | <.01 | <.01 | ||
| <3.8 ng/mL | 1 | 1 | ||
| ≥3.8 ng/mL | 1.48 (1.11-1.96) | 1.52 (1.15-2.01) | ||
| CA19-9 | <.01 | <.01 | ||
| <174.7 U/mL | 1 | 1 | ||
| ≥174.7 U/mL | 1.51 (1.12-2.04) | 1.79 (1.35-2.37) | ||
| DpR within 12 weeks | .02 | <.01 | ||
| <40% | 1 | 1 | ||
| ≥40% | 0.67 (0.48-0.94) | 0.64 (0.46-0.90) | ||
Abbreviations: CI: confidence interval; GC: gemcitabine plus cisplatin; GS: gemcitabine plus S-1; ECOG PS: Eastern Cooperative Oncology Group performance status; CEA: serum carcinoembryonic antigen; CA19-9: serum carbohydrate antigen 19-9; DpR: depth of response.